Evaluating Epidemiological and Physical Risk Factors in the Development of Chemotherapy-induced Peripheral Neuropathy (CIPN): An In-depth Systematic Review and Meta-analysis

Year : 2024 | Volume :01 | Issue : 02 | Page : 10-21
By

    Reeta Khuresha

  1. Researcher, Yamuna Institute of Nursing, Haryana, India

Abstract

Background of study: Chemotherapy-induced peripheral neuropathy (CIPN) encompasses a range of adverse effects caused by various cytotoxic medications and stands as a primary source of pain among individuals who have survived cancer. In instances of pronounced and sudden CIPN, it might become necessary to diminish chemotherapy dosages or discontinue their application. Currently, no efficacious strategy exists for proactively preventing CIPN, managing established chronic CIPN is constrained, and the risk factors associated with CIPN are also transient and elusive. Objectives of the study: The aim is to identify the epidemiological and physiological risk elements associated with chemotherapy-induced peripheral neuropathy in adults. Research methodology: A systematic review was conducted to locate research articles detailing the risk factors associated with chemotherapy-induced peripheral neuropathy (CIPN). The exploration involved searching through various databases, including Delnet, RemoteXS (PGIMER), Ebsco, Wiley online library, Medline, PubMed, and Web of Knowledge, to find relevant sources. A random-effects meta-regression approach was employed. The quality of the studies was evaluated using the CONSORT and STROBE guidelines, along with adherence to PRISMA guidance. Conclusion and results: This systematic review encompassed 133 research studies, incorporating data from a total of 12,378 patients for the purpose of meta-analysis. A qualitative synthesis was performed to outline factors that were found to influence the risk of chemotherapy-induced peripheral neuropathy (CIPN). Among the 133 studies, 68 of them elucidated distinct risk elements contributing to CIPN. In terms of epidemiological factors, 19 studies highlighted aspects such as age (with a focus on older adults), gender (with females displaying a greater susceptibility to CIPN development), and BMI (with obesity and overweight status being implicated). Physical factors, identified in 17 studies out of the total 133, encompassed characteristics like general weakness, fatigue, elevated distress scores, reduced participation in moderate to vigorous physical activity (MVPA), sleep disturbances, shorter stature, increased body weight, impact on health-related quality of life (HRQOL), and a history of smoking.

Keywords: Chemotherapy-induced peripheral neuropathy (CIPN), epidemiological, physical, risk factors, systematic review, meta-analysis

[This article belongs to International Journal of Oncological Nursing and Practices(ijonnp)]

How to cite this article: Reeta Khuresha.Evaluating Epidemiological and Physical Risk Factors in the Development of Chemotherapy-induced Peripheral Neuropathy (CIPN): An In-depth Systematic Review and Meta-analysis.International Journal of Oncological Nursing and Practices.2024; 01(02):10-21.
How to cite this URL: Reeta Khuresha , Evaluating Epidemiological and Physical Risk Factors in the Development of Chemotherapy-induced Peripheral Neuropathy (CIPN): An In-depth Systematic Review and Meta-analysis ijonnp 2024 {cited 2024 Jan 01};01:10-21. Available from: https://journals.stmjournals.com/ijonnp/article=2024/view=130271


References

  1. Argyriou AA, et al. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care. 2007; 16(3): 231–
  2. Abramowski M Chemotherapy-induced neuropathic pain. J Adv Pract Oncol. 2010; 1: 279–283.
  3. Alberti P, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. 2014 Jan; 5(1): 257– doi: 10.1093/annonc/mdt409.
  4. Alberts DS, Noel J Cispaltin-associated neurotoxicity: can it be prevented? Anticancer Drugs. 1995; 6(3): 369–383.
  5. American Cancer Society. (2005). Pain management pocket tool. [Online]. Retrieved from http://www.cancer.org/docroot/PRO/content/PRO_1_1_Pain_Management_Pocket_Tool.asp.
  6. Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C et al. Adult cancer pain. J Natl Compr Canc Netw. 2013 Aug;11(8):992–1022. doi: 10.6004/jnccn.2013.0119.
  7. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao J Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Trea. 2016 Sep; 159(2): 327–33.
  8. Braunwald Eugene, et al. Harrisons’s Principles of Internal Medicine. 15th Edn. McGraw-Hill; 2001.
  9. Cavaletti Guido, Marmiroli Chemotherapy-induced peripheral neurotoxicity. Nat RevNeurol. 2010 Dec; 6(12): 657–666.
  10. Chan Jenny Tse Kwan, Jones Chemotherapy: adding to the risk of falls? JPharmPract Res. 2017 Dec; 47(6): 471–474.
  11. Cliff J, Jorgensen AL, Lord R, Azam The molecular genetics of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Dec; 120: 127–140. © 2017 Elsevier B.V. All rights reserved.
  12. Del ABC, Pino B Chemotherapy-induced Peripheral Neuropathy. NCI Cancer Bulletin. 2010 Feb23; 7(4): 6.
  13. Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007 Jul;130(1-2):144–56. doi: 10.1016/j.pain.2007.01.014. Erratum in: Pain. 2009 Mar;142(1–2):169.
  14. Ewertz Marianne, Qvortrup Camilla, Eckhoff Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015 May; 54(5): 587–591.
  15. Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, Pijnenborg, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014 Dec; 135(3): 510– doi: 10.1016/j.ygyno.2014.09.016. Epub 30 September 2014.
  16. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999 May 15;353(9165):1695–700. doi: 10.1016/S0140-6736(99)01310-0.
  17. Hilkens PH, Verweij J, Vecht CJ, et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol. 1997; 8(2): 187–190. [PubMed]
  18. Foley KM. The treatment of pain in the patient with cancer. CA Cancer J Clin. 1986 Jul-Aug;36(4):194-215. doi: 10.3322/canjclin.36.4.194.
  19. Kerckhove N, Collin A, Condé S. Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol. 2017 Feb 24; 8: Date of Electronic Publication: 24 February 2017 (Print Publication: 2017).
  20. Marrs J, Newton S. Updating your peripheral neuropathy “know-how”. Clin J Oncol Nurs. 2003 May-Jun;7(3):299-303. doi: 10.1188/03.CJON.299-303.
  21. Miltenburg NC, Boogerd Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014 Aug; 40(7): 872–82. doi: 10.1016/j.ctrv.2014.04.004. Epub 18 April 2014.
  22. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011; 118(17): 4519–4529. [PubMed].
  23. Wen PY, Schiff D, Lee EQ. Neurologic Complications of Cancer Therapy. New York: Demos Medical; 2012.
  24. Pignataro A Chemotherapy induced peripheral neuropathy: risk factors, pathophysiology, assessment, and potential physical therapy interventions. Rehab Oncol. 2010; 28(2): 10–18. [Context Link]
  25. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec; 155(12): 2461– Retrieved 23 September 2014 from Cancer Research UK, University of Edinburgh, Edinburgh, Scotland, UK. Electronic address: [email protected].
  26. Velasco Roser, Petit Josep, et al. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst. 2010 Mar; 15(1): 17–
  27. Wilkes Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs. 2007; 23(3):
    162–173.
  28. Windebank AJ, Grisold Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008; 13(1): 27–46.[PubMed]
  29. Zedan AH, Vilholm O Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. Basic Clin Pharmacol Toxicol. 2014 Aug; 115(2): 193–200. doi: 10.1111/bcpt.
    12262. Epub 24, May 2014.
Regular Issue Subscription Review Article
Volume 01
Issue 02
Received October 28, 2023
Accepted December 11, 2023
Published January 1, 2024
Views: 75